Clinical Trials · NCT06847399
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Johns Hopkins University
- Enrollment
- 105
- Start date
- Sep 2025
- Locations
- 1 site, United States
- Primary endpoint
- Percent initial weight loss